BDI, Allison Pancreatic Cancer Drug Clinical Phase 3 Progressing Well with US FDA... "Receiving Data Regularly"

[Asia Economy Reporter Hyunseok Yoo] Vidi AI announced on the 15th that the Phase 3 clinical trial of the pancreatic cancer treatment new drug ‘Glufosfamide,’ being conducted by ‘Ellison Pharmaceuticals’ (Ellison) in the United States, is progressing smoothly.

Ellison recently sent a letter to Vidi AI explaining that they are regularly receiving data related to the Phase 3 clinical trial from the testing institution and that no safety-related issues have occurred so far.

Vidi AI Chairman Seungman Ahn plans to visit Ellison’s headquarters in the United States within this month to check the progress of the Glufosfamide Phase 3 clinical trial and discuss close and efficient cooperation measures between Vidi AI and Ellison.

Dr. Seonjin Kim of PlatBio, known as the top authority among clinical trial execution experts, will also join this Phase 3 trial. Last month, Vidi AI signed a joint development agreement with Dr. Kim’s PlatBio to revitalize its bio business.

Dr. Kim has designed and successfully completed clinical trials for 12 types of anticancer new drugs. Last year, he joined Kolon TissueGene and led the resumption of the Phase 3 clinical trial of Invossa with the U.S. Food and Drug Administration (FDA), which had been put on hold.

A Vidi AI official said, “Although affected by the spread of COVID-19, the Phase 3 clinical trial of Glufosfamide being promoted by Ellison is returning to almost normal levels,” and added, “Ellison is also exploring various options, including an IPO, to raise additional funds for the clinical trial.”

He continued, “Recently, Dr. Kim met with Chairman Ahn to share information about the bio business Vidi AI is promoting and promised to support the anticancer pipeline, including Glufosfamide currently being developed by Ellison, to achieve good results in clinical trials.”

This content was produced with the assistance of AI translation services.